Recombinant glucocerebrosidase
Velaglucerase alfa
Brand names: VPRIV
Adult dose
Dose: 60 units/kg IV every 2 weeks
Route: IV
Frequency: q2w
Clinical pearls
- Type 1 Gaucher disease — enzyme replacement
- Specialist metabolic / haem
Contraindications
- Severe hypersensitivity
Side effects
- Infusion reactions
- Headache
- Pyrexia
- Bone pain
- Nausea
Monitoring
- Hb
- Platelets
- Liver/spleen volumes
- Bone disease
Reference: BNF; NICE; SmPC; https://bnf.nice.org.uk/drugs/velaglucerase-alfa/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO